Fig. 5: Amlexanox did not reduce the expression of pro-inflammatory markers but reduced the phosphorylation of STAT2. | Cell Death Discovery

Fig. 5: Amlexanox did not reduce the expression of pro-inflammatory markers but reduced the phosphorylation of STAT2.

From: Development of translational read-through-inducing drugs as novel therapeutic options for patients with Fanconi anemia

Fig. 5: Amlexanox did not reduce the expression of pro-inflammatory markers but reduced the phosphorylation of STAT2.

Pro-inflammatory cytokines IL-6 (A, n = 3) and TNFα (B, n = 6), and mRNA expression levels in FA-A mutated LCL, after 24 h incubation with amlexanox 25μM (AMX), parthenolide 1μM (PT), hydrocortisone 20μg/ml (HC), NF-κB activation inhibitor 20 nM (NF-κBin), ataluren 5μM. pSTAT2 and STAT2 protein expression levels after AMX, PT, HC and NF-κBin (C, n = 5), and ATA (D, n = 4); expression of p53 (E, n = 4). Data are mean ± SEM. Welch’s ANOVA test (A, B), or mixed effect analysis (C, E) or one-way ANOVA (D) were used (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).

Back to article page